Expand RNXT Menu
RNXT MENU

RNXT Latest Press Releases

-- May 28, 2026 --

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer Globe Newswire 8:30 AM

-- May 26, 2026 --

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting Globe Newswire 8:32 AM

-- May 19, 2026 --

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th Globe Newswire 8:30 AM

-- May 14, 2026 --

RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter Globe Newswire 4:05 PM

-- April 29, 2026 --

RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET Globe Newswire 8:30 AM

-- April 23, 2026 --

RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting Globe Newswire 8:30 AM

-- April 14, 2026 --

Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting Globe Newswire 8:30 AM

-- April 8, 2026 --

RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum Globe Newswire 8:30 AM

-- April 1, 2026 --

RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 Globe Newswire 2:20 PM

-- March 30, 2026 --

RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- March 26, 2026 --

RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment Globe Newswire 8:30 AM

-- March 23, 2026 --

RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement Globe Newswire 8:30 AM

-- March 20, 2026 --

RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET Globe Newswire 8:30 AM

-- March 18, 2026 --

RenovoRx Announces $10 Million at Market Private Placement Globe Newswire 8:35 AM

-- February 27, 2026 --

RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum Globe Newswire 8:30 AM

-- February 26, 2026 --

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting Globe Newswire 8:30 AM

-- February 10, 2026 --

RenovoRx Establishes RenovoCath Medical Advisory Board Globe Newswire 8:30 AM

-- February 5, 2026 --

RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer Globe Newswire 8:30 AM

-- February 4, 2026 --

RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting Globe Newswire 8:30 AM

-- January 28, 2026 --

RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting Globe Newswire 8:30 AM

-- January 20, 2026 --

RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center Globe Newswire 8:30 AM

-- January 14, 2026 --

RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 Globe Newswire 8:30 AM

-- January 8, 2026 --

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech Globe Newswire 12:08 PM
RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 Globe Newswire 8:30 AM
Market Data Delayed 15 Minutes